19:34 , Oct 5, 2018 |  BC Week In Review  |  Financial News

Kala raises $61.9M follow-on

Kala Pharmaceuticals Inc. (NASDAQ:KALA) raised $61.9 million on Oct. 3 through the sale of 7.5 million shares at $8.25 in a follow-on underwritten by J.P. Morgan, BofA Merrill Lynch, Jefferies, Cantor Fitzgerald, Wedbush PacGrow and...
19:09 , Oct 3, 2018 |  BC Extra  |  Financial News

GW, Epizyme, Kala price follow-ons

GW Pharmaceuticals plc (NASDAQ:GWPH), Epizyme Inc. (NASDAQ:EPZM) and Kala Pharmaceuticals Inc. (NASDAQ:KALA) each priced follow-ons late Tuesday, raising a total of $437 million. GW raised $300 million through the sale of 1.9 million ADSs at...
21:18 , Jan 5, 2018 |  BC Week In Review  |  Financial News

OptiNose draws down $75M in debt financing

Ear, nose and throat allergy company OptiNose Inc. (NASDAQ:OPTN) said on Jan. 2 it entered a $100 million debt financing agreement with Athyrium Capital Management. At close, $75 million in senior secured notes were issued....
00:11 , Dec 2, 2017 |  BC Extra  |  Financial News

Athyrium, Neuberger close $2B third fund

Athyrium Capital Management and Neuberger Berman closed Athyrium Opportunities Fund III at $2.025 billion. The new fund will make investments in commercial-stage companies across the healthcare ecosystem, with more than 50% of the capital expected...
00:06 , Dec 2, 2017 |  BioCentury  |  Finance

Opportunity sizing

With strong support from existing and new LPs and an attractively priced healthcare sector to play in, Athyrium Capital Management and Neuberger Berman went big for their third co-managed fund. Athyrium Opportunities Fund III clocked...
07:00 , May 9, 2016 |  BC Week In Review  |  Financial News

Relypsa completes debt financing

Relypsa Inc. (NASDAQ:RLYP), Redwood City, Calif.   Business: Endocrine/Metabolic   Date completed: 2016-05-03   Type: Debt financing   Raised: $150 million   Shares outstanding prior: 44.7 million   Investors: Athyrium Capital Management; Healthcare Royalty Partners...
01:45 , May 5, 2016 |  BC Extra  |  Financial News

Relypsa sinks after debt financing

Relypsa Inc. (NASDAQ:RLYP) sank $3.32 (19%) to $14 on Wednesday after it closed a $150 million debt offering underwritten by Athyrium Capital Management and Healthcare Royalty Partners. The debt matures on April 27, 2022, and...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Financial News

Halozyme completes debt financing

Halozyme Therapeutics Inc. (NASDAQ:HALO), San Diego, Calif.   Business: Endocrine/Metabolic, Cancer, Dermatology   Date completed: 2016-01-26   Type: Debt financing   Raised: $150 million   Investors: Pharmakon Advisors; Athyrium Capital Management   Note: The loan...
08:00 , Jan 11, 2016 |  BC Week In Review  |  Financial News

Halozyme financial update

Halozyme Therapeutics Inc. (NASDAQ:HALO), San Diego, Calif.   Business: Endocrine/Metabolic, Cancer, Dermatology   Date announced: 2016-01-04   Note: Halozyme secured a $150 million credit facility from Pharmakon Advisors and Athyrium Capital Management. The loan bears...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Financial News

Athyrium Capital Management financial update

Athyrium Capital Management , New York, N.Y.   Business: Finance   Date announced: 2015-07-20   Note: Athyrium Capital Management and partner Neuberger Berman closed a $1.2 billion fund that will invest in commercial stage healthcare...